A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma

Published:2018 Issue:6 Volume:94 Page:329-339
ISSN:0030-2414
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Thomas Melanie B.,Garrett-Mayer Elizabeth,Anis Munazza,Anderton Kate,Bentz Tricia,Edwards Andie,Brisendine Alan,Weiss Geoffrey,Siegel Abby B.,Bendell Johanna,Baron Ari,Duddalwar Vinay,El-Khoueiry Anthony

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference71 articles.

1. Zhu AX: Current status of hepatocellular carcinoma in the United States. Chin Clin Oncol 2013; 2: 45.

2. Maillard E: Epidemiology, natural history and pathogenesis of hepatocellular carcinoma (in French). Cancer Radiother 2011; 15: 3–6.

3. Yuen MF, Hou JL, Chutaputti A; Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma: Hepatocellular carcinoma in the Asia Pacific region. J Gastroenterol Hepatol 2009; 24: 346–353.

4. Siegel RL, Miller KD, Jemal A: Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7–30.

5. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–390.

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Therapies for Hepatocellular Carcinoma in India;Journal of Clinical and Experimental Hepatology;2024-11

2. Targeted Therapies for Hepatocellular Carcinoma Treatment;Liver Cancer - Multidisciplinary Approach;2024-09-11

3. Mechanisms and therapeutic targets of ErbB family receptors in hepatocellular carcinoma: a narrative review;TRANSL CANCER RES;2024

4. Insights in Molecular Therapies for Hepatocellular Carcinoma;Cancers;2024-05-10

5. New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma—Today and Tomorrow;International Journal of Molecular Sciences;2024-01-25